EP3863635A4 - Thyroid hormone receptor beta agonist compounds - Google Patents
Thyroid hormone receptor beta agonist compounds Download PDFInfo
- Publication number
- EP3863635A4 EP3863635A4 EP19870196.3A EP19870196A EP3863635A4 EP 3863635 A4 EP3863635 A4 EP 3863635A4 EP 19870196 A EP19870196 A EP 19870196A EP 3863635 A4 EP3863635 A4 EP 3863635A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- hormone receptor
- thyroid hormone
- receptor beta
- agonist compounds
- beta agonist
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862745195P | 2018-10-12 | 2018-10-12 | |
| PCT/US2019/055689 WO2020077123A1 (en) | 2018-10-12 | 2019-10-10 | Thyroid hormone receptor beta agonist compounds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EP3863635A1 EP3863635A1 (en) | 2021-08-18 |
| EP3863635A4 true EP3863635A4 (en) | 2022-06-15 |
Family
ID=70161488
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP19870196.3A Pending EP3863635A4 (en) | 2018-10-12 | 2019-10-10 | Thyroid hormone receptor beta agonist compounds |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US11203587B2 (en) |
| EP (1) | EP3863635A4 (en) |
| JP (1) | JP2022504620A (en) |
| CN (1) | CN112839655A (en) |
| AR (1) | AR116694A1 (en) |
| AU (1) | AU2019357618A1 (en) |
| CA (1) | CA3114015A1 (en) |
| MA (1) | MA53868A (en) |
| WO (1) | WO2020077123A1 (en) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111320609A (en) | 2018-12-13 | 2020-06-23 | 拓臻股份有限公司 | THR β receptor agonist compound and preparation method and application thereof |
| BR112021021718A2 (en) | 2019-05-08 | 2022-01-18 | Aligos Therapeutics Inc | Thr-ss modulators and methods of using them |
| CN113278013B (en) * | 2020-02-20 | 2022-09-23 | 昆药集团股份有限公司 | 2, 6-disubstituted 1,2, 4-triazine-3, 5-diketone compound and preparation method and application thereof |
| BR112022024678A2 (en) * | 2020-06-02 | 2022-12-27 | Chengdu kanghong pharmaceutical co ltd | INNOVATIVE THYROID HORMONE SS RECEPTOR AGONIST |
| WO2022053028A1 (en) * | 2020-09-10 | 2022-03-17 | 南京明德新药研发有限公司 | 1,2,4-triazine-3,5(2h,4h)-diketone compound and application thereof |
| CN112645936B (en) * | 2020-12-17 | 2022-03-01 | 山东第一医科大学(山东省医学科学院) | Substituted pyridazinone compound and use thereof |
| PE20240097A1 (en) * | 2021-03-03 | 2024-01-18 | Terns Pharmaceuticals Inc | THYROID HORMONE RECEPTOR BETA AGONIST COMPOUNDS |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6787652B1 (en) | 1999-09-30 | 2004-09-07 | Pfizer, Inc. | 6-Azauracil derivatives as thyroid receptor ligands |
| PT1088819E (en) * | 1999-09-30 | 2005-09-30 | Pfizer Prod Inc | 6-AZAURACYL DERIVATIVES AS LIGNED FROM TIROIDE RECEPTORS |
| EP1471049A4 (en) | 2002-01-30 | 2006-08-16 | Kissei Pharmaceutical | Novel thyroid hormone receptor ligand, medicinal compositions containing the same and use thereof |
| WO2003094845A2 (en) | 2002-05-08 | 2003-11-20 | Bristol-Myers Squibb Company | Pyridine-based thyroid receptor ligands |
| US7572799B2 (en) | 2003-11-24 | 2009-08-11 | Pfizer Inc | Pyrazolo[4,3-d]pyrimidines as Phosphodiesterase Inhibitors |
| FR2882750B1 (en) * | 2005-03-03 | 2007-05-11 | Pierre Fabre Medicament Sa | 1,2,4-TRIAZINE DERIVATIVES, THEIR PREPARATION AND THEIR APPLICATION IN HUMAN THERAPEUTICS |
| GB0513692D0 (en) | 2005-07-04 | 2005-08-10 | Karobio Ab | Novel pharmaceutical compositions |
| DK1919878T3 (en) | 2005-07-21 | 2010-10-25 | Hoffmann La Roche | Pyridazine derivatives as thyroid hormone receptor agonists |
| FR2933979B1 (en) * | 2008-07-15 | 2012-08-24 | Pf Medicament | TRIAZINE AND URACIL DERIVATIVES, THEIR PREPARATION AND THEIR APPLICATION IN HUMAN THERAPY |
| MX2011011028A (en) | 2009-04-20 | 2011-11-02 | Mitsubishi Tanabe Pharma Corp | Novel thyroid hormone î² receptor agonist. |
| WO2011038207A1 (en) | 2009-09-25 | 2011-03-31 | Metabasis Therapeutics, Inc. | Phosphorus-containing thyroid hormone receptor agonists and methods of use |
| HUE033032T2 (en) * | 2011-11-14 | 2017-11-28 | Ignyta Inc | Uracil derivatives as axl and c-met kinase inhibitors |
| CN103130723B (en) | 2011-11-30 | 2015-01-14 | 成都地奥制药集团有限公司 | Poly (aenosine diphosphate glucose pyrophospheralase (ADP)-ribose) polymerase inhibitor |
| JP6814730B2 (en) * | 2014-09-05 | 2021-01-20 | ジェネンテック， インコーポレイテッド | Therapeutic compounds and their use |
| ES2924257T3 (en) | 2016-10-18 | 2022-10-05 | Madrigal Pharmaceuticals Inc | Methods of treating liver disorders or lipid disorders with a THR-beta agonist |
| US11485729B2 (en) | 2018-01-23 | 2022-11-01 | Shenzhen Targetrx, Inc. | Substituted pyridazinone compound |
| AU2019287679B2 (en) | 2018-06-12 | 2022-04-21 | Xizang Haisco Pharmaceutical Co., Ltd. | Thyroid hormone receptor agonists and uses thereof |
| WO2020041741A1 (en) | 2018-08-24 | 2020-02-27 | Terns, Inc. | Thyroid hormone receptor beta agonist compounds |
| CN112739692A (en) | 2018-10-12 | 2021-04-30 | 益方生物科技(上海)股份有限公司 | Thyroid hormone receptor agonists |
| CN111320609A (en) | 2018-12-13 | 2020-06-23 | 拓臻股份有限公司 | THR β receptor agonist compound and preparation method and application thereof |
| CN111484481A (en) | 2019-01-26 | 2020-08-04 | 察略盛医药科技(上海)有限公司 | Pyridazinone derivative, preparation method and medical application thereof |
| US20220162161A1 (en) | 2019-02-21 | 2022-05-26 | Nanjing Ruijie Pharma Co., Ltd. | Novel compounds and their uses as thyroid hormone receptor agonists |
| WO2020239076A1 (en) | 2019-05-29 | 2020-12-03 | 南京明德新药研发有限公司 | Pyridazinone derivatives as thyroxine receptor-β agonists and application thereof |
-
2019
- 2019-10-10 CA CA3114015A patent/CA3114015A1/en active Pending
- 2019-10-10 MA MA053868A patent/MA53868A/en unknown
- 2019-10-10 AU AU2019357618A patent/AU2019357618A1/en active Pending
- 2019-10-10 JP JP2021519726A patent/JP2022504620A/en active Pending
- 2019-10-10 CN CN201980067301.7A patent/CN112839655A/en active Pending
- 2019-10-10 WO PCT/US2019/055689 patent/WO2020077123A1/en unknown
- 2019-10-10 US US16/598,978 patent/US11203587B2/en active Active
- 2019-10-10 EP EP19870196.3A patent/EP3863635A4/en active Pending
- 2019-10-11 AR ARP190102912A patent/AR116694A1/en unknown
-
2022
- 2022-06-30 US US17/855,672 patent/US20220348561A1/en not_active Abandoned
Non-Patent Citations (1)
| Title |
|---|
| No further relevant documents disclosed * |
Also Published As
| Publication number | Publication date |
|---|---|
| CA3114015A1 (en) | 2020-04-16 |
| WO2020077123A1 (en) | 2020-04-16 |
| MA53868A (en) | 2021-08-18 |
| EP3863635A1 (en) | 2021-08-18 |
| CN112839655A (en) | 2021-05-25 |
| TW202027748A (en) | 2020-08-01 |
| US20220348561A1 (en) | 2022-11-03 |
| JP2022504620A (en) | 2022-01-13 |
| US11203587B2 (en) | 2021-12-21 |
| AU2019357618A1 (en) | 2021-04-29 |
| AR116694A1 (en) | 2021-06-02 |
| US20200115362A1 (en) | 2020-04-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3864013A4 (en) | Thyroid hormone receptor agonists | |
| EP3840755A4 (en) | Thyroid hormone receptor beta agonist compounds | |
| EP3863635A4 (en) | Thyroid hormone receptor beta agonist compounds | |
| EP4017875A4 (en) | Thyroid hormone receptor beta agonist compounds | |
| EP4069686A4 (en) | Glp-1 receptor agonist | |
| EP3807267A4 (en) | Thyroid hormone receptor agonists and uses thereof | |
| EP3927693A4 (en) | Novel compounds and their uses as thyroid hormone receptor agonists | |
| EP4028008A4 (en) | Thyroid hormone receptor beta agonist compounds | |
| IL283362A (en) | Thrβ receptor agonist compound and preparation method and use thereof | |
| EP4058445A4 (en) | Glp-1 receptor agonist and use thereof | |
| TWI800478B (en) | Triple glucagon/glp-1/gip receptor agonist | |
| EP4036090A4 (en) | Chemical compound as thyroid hormone beta receptor agonist and use thereof | |
| EP3650449A4 (en) | Fxr receptor agonist | |
| EP3793608A4 (en) | Anti-cancer nuclear hormone receptor-targeting compounds | |
| EP3632910A4 (en) | Lactam compound as fxr receptor agonist | |
| IL279504A (en) | Gip/glp1 agonist compositions | |
| EP3849610A4 (en) | Anti-il4 receptor antibodies for veterinary use | |
| IL281201A (en) | Anti-trem-2 agonist antibodies | |
| EP3445769A4 (en) | Thyroid hormone receptor agonist and use thereof | |
| IL280367A (en) | Cd226 agonist antibodies | |
| EP3757091A4 (en) | Compound having s1p5 receptor agonist activity | |
| IL280199A (en) | Receptor for vista | |
| EP3549948A4 (en) | Agonist peptide for adiponectin receptor | |
| EP4086267A4 (en) | Liver-targeting compound having thyroid hormone receptor agonist characteristics and pharmaceutical composition thereof | |
| EP3750879A4 (en) | Prostacyclin receptor agonist |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
| 17P | Request for examination filed |
Effective date: 20210422 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40058390 Country of ref document: HK |
|
| A4 | Supplementary search report drawn up and despatched |
Effective date: 20220518 |
|
| RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61P 5/02 20060101ALI20220512BHEP Ipc: A61K 31/53 20060101ALI20220512BHEP Ipc: A61K 31/50 20060101ALI20220512BHEP Ipc: C07D 403/12 20060101ALI20220512BHEP Ipc: C07D 403/10 20060101AFI20220512BHEP |